Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
cardiotoxicity
chimeric antigen receptor T-cell therapy
cytokine release syndrome
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
24 12 2019
24 12 2019
Historique:
received:
09
06
2019
revised:
09
10
2019
accepted:
31
10
2019
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
23
5
2020
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of patients with relapsed and refractory hematologic malignancies and is increasingly investigated as a therapeutic option of other malignancies. The main adverse effect of CAR T-cell therapy is potentially life-threatening cytokine release syndrome (CRS). Clinical cardiovascular (CV) manifestations of CRS include tachycardia, hypotension, troponin elevation, reduced left ventricular ejection fraction, pulmonary edema, and cardiogenic shock. Although insults related to CRS toxicity might be transient and reversible in most instances in patients with adequate CV reserve, they can be particularly challenging in higher-risk, often elderly patients with pre-existing CV disease. As the use of CAR T-cell therapy expands to include a wider patient population, careful patient selection, pre-treatment cardiac evaluation, and CV risk stratification should be considered within the CAR T-cell treatment protocol. Early diagnosis and management of CV complications in patients with CRS require awareness and multidisciplinary collaboration.
Identifiants
pubmed: 31856973
pii: S0735-1097(19)38386-X
doi: 10.1016/j.jacc.2019.10.049
pmc: PMC8211027
mid: NIHMS1706147
pii:
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3153-3163Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
Biol Blood Marrow Transplant. 2018 Aug;24(8):1590-1595
pubmed: 29772353
Nat Rev Immunol. 2018 Oct;18(10):605-616
pubmed: 30046149
Cancer Discov. 2016 Jun;6(6):664-79
pubmed: 27076371
Blood. 2017 Dec 7;130(23):2569-2572
pubmed: 29074500
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Lancet. 2004 Jan 17;363(9404):203-9
pubmed: 14738793
Cardiol Clin. 2019 Nov;37(4):385-397
pubmed: 31587780
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Oncologist. 2017 Feb;22(2):213-221
pubmed: 28159866
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
N Engl J Med. 2017 Oct 5;377(14):1313-1315
pubmed: 28902570
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Ther Clin Risk Manag. 2019 Feb 28;15:323-335
pubmed: 30880998
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
N Engl J Med. 2008 Jun 19;358(25):2704-15
pubmed: 18565863
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Immunother. 2012 May;35(4):299-308
pubmed: 22495387
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Blood. 2013 Aug 8;122(6):863-71
pubmed: 23770775
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
Biomark Res. 2018 Jan 22;6:4
pubmed: 29387417
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
Cell Death Dis. 2018 Sep 4;9(9):897
pubmed: 30181581